Cephalexin Dosing and Clinical Considerations for Soft Tissue Infections

Adult Dosing Recommendations

• For mild to moderate skin and soft tissue infections, the standard adult dose is 500 mg orally every 6 hours (four times daily) 1
• The typical duration of therapy for skin and soft tissue infections is 7 days, but may be extended if the infection has not improved within this time period 2, 3

Clinical Considerations

• Cephalexin provides good coverage against methicillin-susceptible Staphylococcus aureus (MSSA) and streptococci, which are common pathogens in soft tissue infections 4, 1
• Cephalexin is not effective against methicillin-resistant Staphylococcus aureus (MRSA); alternative agents should be considered if MRSA is suspected 1

Special Situations

• For recurrent soft tissue infections, obtain cultures before starting antibiotics 3
• For soft tissue infections associated with animal or human bites, amoxicillin-clavulanate is preferred over cephalexin due to better coverage against Pasteurella multocida and anaerobes 5, 6
• For diabetic foot infections or other complicated soft tissue infections, broader spectrum antibiotics may be necessary 7

Important Caveats

• For patients with immediate hypersensitivity reactions to penicillins, cross-reactivity with cephalexin is possible, and alternative agents should be considered 1

Cephalexin Dosing and Usage Guidelines

Standard Adult Dosing

• The Infectious Diseases Society of America recommends cephalexin 500 mg orally every 6 hours (four times daily) for mild to moderate soft tissue infections 8
• For non-purulent infections (cellulitis, erysipelas) without risk factors for MRSA, cephalexin 500 mg four times daily for 7 days is recommended 8

Pediatric Dosing

• The standard pediatric dosage is 25-50 mg/kg/day divided into 3-4 doses (every 6-8 hours) for children 8

Critical Coverage Considerations

• If MRSA is suspected, alternative agents such as trimethoprim-sulfamethoxazole, doxycycline, or clindamycin should be used instead, as cephalexin is only effective against methicillin-susceptible Staphylococcus aureus (MSSA) and streptococci 8
• For patients with purulent infections (abscesses, carbuncles) and systemically unwell, or failed initial treatment, an MRSA-active agent should be used, not cephalexin 8

Special Considerations

• The IDSA guidelines suggest that for penicillin-allergic patients (except those with immediate hypersensitivity), cefazolin or cephalexin are appropriate alternatives to nafcillin/oxacillin 8